SME Times News Bureau | 20 Jun, 2017
Pharma major Zydus Cadila on Monday said it has received the final approval from the US Food and Drug Administration (FDA) to sell Eletriptan Hydrobromide tablets, used in the treatment of migraine.
According to the company, the drug with strengths 20mg and 40mg will be produced at the group's formulations manufacturing facility at the Pharma SEZ (special economic zone) in Ahmedabad.
"The group now has more than 120 approvals and has so far filed over 300 ANDAs (abbreviated new drug applications ) since the commencement of the filing process in FY 2003-04," the firm said in a regulatory filing with the BSE.
